Terence Friedlander, MD, and Vadim Koshkin, MD, both of the University of California, San Francisco, highlight the 18-month outcomes data from the EV-103 study on enfortumab vedotin plus pembrolizumab as first-line treatment for metastatic urothelial carcinoma.